How to buy GlaxoSmithKline (GSK) stock

GlaxoSmithKline plc is a drug manufacturers-general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. GlaxoSmithKline employs 94,066 staff and has a trailing 12-month revenue of around 0.00.

GlaxoSmithKline stock price (NYSE: GSK)

Use our graph to track the performance of GSK stocks over time.

GlaxoSmithKline shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$38.90
52-week range	$31.82 - $41.44
50-day moving average	$39.80
200-day moving average	$37.65
Wall St. target price	$49.17
PE ratio	13.8037
Dividend yield	$0.8 (2.03%)
Earnings per share (TTM)	$2.84

Buy GlaxoSmithKline shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy GlaxoSmithKline stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of GlaxoSmithKline plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GlaxoSmithKline price performance over time

Historical closes compared with the close of $38.9 from 2021-06-04

1 week (2021-07-16)	N/A
1 month (2021-06-25)	-2.21%
3 months (2021-04-27)	3.10%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Is GlaxoSmithKline under- or over-valued?

Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

GlaxoSmithKline's P/E ratio

GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, GlaxoSmithKline shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

GlaxoSmithKline's PEG ratio

GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.3421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

GlaxoSmithKline's EBITDA

GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.7 billion.

The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.

GlaxoSmithKline financials

Revenue TTM	$32.4 billion
Operating margin TTM	23.64%
Gross profit TTM	$23.2 billion
Return on assets TTM	5.9%
Return on equity TTM	29.04%
Profit margin	16.21%
Book value	$5.94
Market capitalisation	$98.7 billion

TTM: trailing 12 months

Shorting GlaxoSmithKline shares

There are currently 14.4 million GlaxoSmithKline shares held short by investors – that's known as GlaxoSmithKline's "short interest". This figure is 29.4% down from 20.5 million last month.

There are a few different ways that this level of interest in shorting GlaxoSmithKline shares can be evaluated.

GlaxoSmithKline's "short interest ratio" (SIR)

GlaxoSmithKline's "short interest ratio" (SIR) is the quantity of GlaxoSmithKline shares currently shorted divided by the average quantity of GlaxoSmithKline shares traded daily (recently around 5.1 million). GlaxoSmithKline's SIR currently stands at 2.85. In other words for every 100,000 GlaxoSmithKline shares traded daily on the market, roughly 2850 shares are currently held short.

However GlaxoSmithKline's short interest can also be evaluated against the total number of GlaxoSmithKline shares, or, against the total number of tradable GlaxoSmithKline shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GlaxoSmithKline's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GlaxoSmithKline shares in existence, roughly 10 shares are currently held short) or 0.0059% of the tradable shares (for every 100,000 tradable GlaxoSmithKline shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GlaxoSmithKline.

Find out more about how you can short GlaxoSmithKline stock.

GlaxoSmithKline share dividends

Dividend payout ratio: 79.86% of net profits

Recently GlaxoSmithKline has paid out, on average, around 79.86% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 5.53% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.8 per share.

GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

GlaxoSmithKline's most recent dividend payout was on 7 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 19 May 2021 (the "ex-dividend date").

Have GlaxoSmithKline's shares ever split?

GlaxoSmithKline's shares were split on a 2:1 basis on 11 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.

GlaxoSmithKline share price volatility

Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $31.82 up to $41.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.3983. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).

GlaxoSmithKline overview

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc. ; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.

Frequently asked questions

What percentage of GlaxoSmithKline is owned by insiders or institutions?
Currently 0.013% of GlaxoSmithKline shares are held by insiders and 12.64% by institutions. How many people work for GlaxoSmithKline?
Latest data suggests 94,066 work at GlaxoSmithKline. When does the fiscal year end for GlaxoSmithKline?
GlaxoSmithKline's fiscal year ends in December. Where is GlaxoSmithKline based?
GlaxoSmithKline's address is: 980 Great West Road, Brentford, United Kingdom, TW8 9GS What is GlaxoSmithKline's ISIN number?
GlaxoSmithKline's international securities identification number is: US37733W1053 What is GlaxoSmithKline's CUSIP number?
GlaxoSmithKline's Committee on Uniform Securities Identification Procedures number is: 37733W105